Latest News, Updates & Breaking Headlines
The reduction of US reciprocal tariffs on Indian goods from 25 per cent to 10 per cent is expected to significantly improve the competitiveness of labour-intensive sectors such as pharmaceuticals, electronics, engineering goods, textiles, and gems and jewellery in the American market, industry representatives said.The development follows a US Supreme Court ruling that struck down…
PM Modi and Brazilian President Luiz Inacio Lula da Silva (File photo) Officials are finalising a set of India–Brazil agreements expected to be signed during Brazilian President Luiz Inacio Lula da Silva’s official visit to India next week, with the proposed pacts likely to boost pharmaceutical exports, strengthen cooperation in critical minerals and support the…
NEW DELHI: The Dadachanji Group, which is focused on pharma manufacturing and allied technologies, has forayed into building fully customised machines, medical devices, and automation solutions in pharma, healthcare, and other sectors through KAIRISH Innotech. The company will offer end-to-end capabilities across customised pharma machinery, medical device design and manufacturing, tooling and precision components, robotics…
NEW DELHI: The interim India-US trade arrangement provides certainty and clarity to the domestic pharma sector, with medicines staying outside reciprocal tariffs, and Washington signalling negotiated treatment for generics under Section 232.India plays a critical role in supplying affordable medicines to the US, with shipments of around $10 billion accounting for nearly 35% of its…
The interim India-US trade agreement is expected to strengthen cooperation in pharmaceuticals and medical technology, with industry bodies saying medicine supply chains are closely linked to national security priorities.Strengthening the India-US medicines partnership is important as medicine security is a part of national security, the Indian Pharmaceutical Alliance said on Saturday, welcoming the interim trade…
NEW DELHI: Drug makers are set to gain clarity under the proposed India-US trade agreement, sharpening expansion plans in the world’s most lucrative pharmaceutical market. While the sector was insulated from punitive US tariffs, the generics business of major companies, including Sun Pharma, Dr Reddy’s and Cipla faced significant headwinds in the third quarter ended…
DEA Secretary Anuradha Thakur Economic Affairs secretary Anuradha Thakur expects foreign capital inflows to improve on the back of Budget measures that have been unveiled and is confident that the growth momentum will sustain. Excerpts:Given the challenges that the economy faces, how do you see the growth-inflation dynamics playing out in the short term?■ I…
Ahead of the Union Budget 2026, industry leaders from the pharmaceutical and MedTech sectors have called for a structured funding framework to deepen innovation and research and development (R&D), saying this is critical for realising India’s Viksit Bharat vision.Dr Reddy’s Laboratories Ltd Chairman Satish Reddy said India’s pharmaceutical industry is undergoing a strategic transition from…
Even as global economic uncertainity drags down trade, Indian pharmaceutical exporters are seeing growth in Brazil and Nigeria as both countries are emerging as important overseas markets. Data by the commerce ministry data shows that Nigeria has been a major driver of this shift. During the first eight months of the current financial year, exports…
The impending patent expiry of semaglutide drugs across India, emerging markets and select regulated markets such as Canada and Brazil is expected to create a revenue opportunity of more than Rs 50 billion for generic pharmaceutical companies over the next 12 to 15 months, according to an industry update by Systematix Institutional Research.The report said…
